• Home
  • About
    • Senior Management
    • Board of Directors
    • Scientific Advisory Board
  • Products
    • TNX-201 (oral enteric coated imatinib)
    • TNX-103 (oral levosimendan)
  • Education Center
    • Featured Articles
    • Education Categories
    • Viewpoints
  • Investors/Media
  • Contact
Contact Icon Contact Icon Contact Icon
  • Home
  • About
    • Senior Management
    • Board of Directors
    • Scientific Advisory Board
  • Products
    • TNX-201 (oral enteric coated imatinib)
    • TNX-103 (oral levosimendan)
  • Education Center
    • Featured Articles
    • Education Categories
    • Viewpoints
  • Investors/Media
  • Contact
  • Home
  • About
    • Senior Management
    • Board of Directors
    • Scientific Advisory Board
  • Products
    • TNX-201 (oral enteric coated imatinib)
    • TNX-103 (oral levosimendan)
  • Education Center
    • Featured Articles
    • Education Categories
    • Viewpoints
  • Investors/Media
  • Contact

Education Posts

Group Clinical Trial Science

Article Type: Precision Medicine

Treatment-related Biomarkers in Pulmonary Hypertension

This paper discusses the data for and against the use of molecular biomarkers as an enrichment strategy in future clinical trials in PAH. This is a call for the collection of prospective data to create a biomarker panel that would then be employed in future trials for PAH.

Citation
Swaminathan AC, Dusek AC, McMahon TJ. Treatment-related biomarkers in pulmonary hypertension. Am J Respir Cell Mol Biol. 2015 Jun;52(6):663-73.
Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4491132/

Enhancing Insights into Pulmonary Vascular Disease Through a Precision Medicine Approach

NIH Workshop Summary from leading experts. A review of precision medicine approaches to treatments for PAH including inadequacies of therapy of PAH using the traditional approach, considerations in the conduct of clinical trials for a precision medicine approach, considerations in the design of clinical trials, and pharmaceutical industry challenges with precision medicine clinical trials.

Citation
Newman JH, Rich S, Abman SH, Alexander JH, Barnard J, et. Al. Enhancing Insights into Pulmonary Vascular Disease through a Precision Medicine Approach. A Joint NHLBI-Cardiovascular Medical Research and Education Fund Workshop Report. Am J Respir Crit Care Med. 2017 Jun 15;195(12):1661-1670.
Source: https://pubmed.ncbi.nlm.nih.gov/28430547/
Back Education Center
  • Products
    • TNX-201 (oral enteric coated imatinib)
    • TNX-103 (oral levosimendan)
  • Education Center
    • Featured Articles
    • Education Categories
    • Viewpoints
  • Contact
    • Email

Tenax Therapeutics

Specialty pharmaceutical company focused on identifying and developing therapeutics that address cardio-pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension.

Contact Icon Contact Icon Contact Icon

© Copyright 2023 Tenax Therapeutics. All Rights Reserved.
Site created by Top Shelf Design

  • Privacy Policy
  • Terms of Service